Download SCDM CCDM Exam Dumps Free

Shared by Pickett on 17-06-2026

For More Free Questions and Preparation Resources

Check the Links on Last Page

Question 1

Question Type: MultipleChoice

A Clinical Data Manager reads a protocol for a clinical trial to test the efficacy and safety of a new blood thinner for prevention of secondary cardiac events. The stated endpoint is all-cause mortality at 1 year. Which data element would be required for the efficacy endpoint?

Options:

A- Drug level
B- Coagulation time
C- Cause of death
D- Date of death

Answer:

D

Explanation:

The efficacy endpoint of all-cause mortality at one year directly depends on the date of death for each subject, making Option D -- Date of death the required data element.

According to the GCDMP (Chapter: Clinical Trial Protocols and Data Planning) and ICH E3/E9 Guidelines, the primary efficacy analysis must be based on time-to-event data, particularly when the endpoint involves mortality or survival. The date of death allows accurate calculation of time from randomization to event, essential for survival analysis (e.g., Kaplan-Meier curves).

While cause of death (C) may be collected for safety or secondary analyses, all-cause mortality specifically includes any death regardless of cause. Drug levels (A) and coagulation times (B) may serve as pharmacodynamic or exploratory endpoints but do not directly measure mortality.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Protocol Review, Section 5.4 -- Defining Data Required for Endpoints

ICH E9 -- Statistical Principles for Clinical Trials, Section 2.3 -- Time-to-Event Endpoints

FDA Guidance for Industry: Clinical Trial Endpoints for Drug Development and Approval

Question 2

Question Type: MultipleChoice

Which of the following statements would be BEST included in a data management plan describing the process for making self-evident corrections in a clinical database?

Options:

A- A senior level data manager may make audited changes to the database without further documentation.
B- Self-evident corrections made in the database will be reviewed and approved by a team leader or manager.
C- No changes will be made in the database without a query response signed by the investigator.
D- Self-evident changes may be made per the listed conventions and documented to the investigative site.

Answer:

D

Explanation:

A self-evident correction (SEC) refers to a data correction that is obvious, logical, and unambiguous --- such as correcting an impossible date (e.g., 31-APR-2024) or standardizing a known abbreviation (e.g., ''BP'' to ''Blood Pressure''). According to the Good Clinical Data Management Practices (GCDMP), SECs can be applied by data management staff following pre-approved conventions defined in the Data Management Plan (DMP).

The DMP should explicitly describe the criteria for SECs, including the types of errors eligible for this correction method, the required documentation, and the communication procedure to inform the investigative site. The process must maintain audit trail transparency and ensure that all changes are traceable and justified.

Options A and B suggest unauthorized or informal change procedures, which violate audit and compliance standards. Option C is too restrictive, as it prevents the efficient correction of non-clinical transcription or formatting errors.

Therefore, option D is correct: ''Self-evident changes may be made per the listed conventions and documented to the investigative site.'' This approach aligns with CCDM expectations for balancing efficiency, accuracy, and regulatory compliance.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 6.2 -- Self-Evident Corrections

FDA 21 CFR Part 11 -- Electronic Records; Audit Trails and Traceability Requirements

Question 3

Question Type: MultipleChoice

If database auditing is used for data quality control during a study, which is the optimal timing of the audits?

Options:

A- Immediately following database lock
B- A week or two before database lock
C- After the first few cases have been entered
D- Periodically throughout the study

Answer:

D

Explanation:

Database audits are conducted to ensure ongoing data accuracy, completeness, and compliance throughout the lifecycle of a clinical trial. According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Quality Assurance and Control), quality audits are most effective when performed periodically during study conduct, rather than waiting until study completion.

Performing audits periodically allows early detection of data entry errors, protocol deviations, and system inconsistencies, thereby reducing the risk of large-scale data issues before database lock. This proactive approach aligns with risk-based quality management principles outlined in ICH E6(R2) and ensures corrective actions are implemented in real time.

Options A and B represent reactive quality control, which occurs too late to prevent data issues. Option C (after first few cases) provides initial validation but does not ensure continuous oversight.

Therefore, option D --- ''Periodically throughout the study'' --- represents the optimal and compliant timing for quality audits of the database.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Data Quality Assurance and Control, Section 5.3 -- Ongoing Quality Control and Auditing

ICH E6(R2) GCP, Section 5.1.1 -- Quality Management System and Risk-Based Monitoring

FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.5 -- Data Review and Auditing Practices

Question 4

Question Type: MultipleChoice

QA is conducting an audit on a study for ophthalmology which is ready for lock. Inconsistencies are found between the database and the source. Of the identified fields containing potential data errors, which fields are considered critical for this particular study?

Options:

A- Subject Identifier
B- Concomitant Medications
C- Weight
D- Medical History

Answer:

B

Explanation:

In an ophthalmology clinical study, data criticality is determined by how directly a data element affects safety evaluation, efficacy assessment, and regulatory decision-making. According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Validation and Cleaning), critical data fields are those that:

Have a direct impact on the primary and secondary endpoints, or

Are essential for safety interpretation and adverse event causality assessment.

Among the listed options, Concomitant Medications (Option B) are considered critical data for ophthalmology studies. This is because many ocular treatments and investigational products can interact with systemic or topical medications, potentially affecting ocular response, intraocular

pressure, corneal healing, or visual function outcomes. Any inconsistency in concomitant medication data could directly influence safety conclusions or efficacy interpretations.

Other options, while important, are less critical for this study type:

Subject Identifier (A) is essential for data traceability and audit purposes but is not directly related to safety or efficacy outcomes.

Weight (C) may be relevant in dose-dependent drug trials but is rarely a pivotal variable in ophthalmology, where local administration (eye drops, intraocular injections) is common.

Medical History (D) provides contextual background but does not have the same immediate impact on endpoint analysis as current concomitant treatments that can confound the therapeutic effect or cause ocular adverse events.

Per GCDMP and ICH E6 (R2) GCP guidelines, data validation plans must define critical data fields during study setup, reflecting therapeutic area--specific priorities. For ophthalmology, concomitant medications, ocular assessments (visual acuity, intraocular pressure, retinal thickness, etc.), and adverse events are typically designated as critical fields requiring heightened validation, source verification, and reconciliation accuracy before database lock.

Thus, when QA identifies discrepancies between the CRF and source, the Concomitant Medications field (Option B) is the most critical to address immediately to ensure clinical and regulatory data integrity.

Reference (CCDM-Verified Sources):

Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.4 -- Critical Data Fields and Data Validation Prioritization

ICH E6 (R2) Good Clinical Practice, Section 5.18 -- Monitoring and Source Data Verification

FDA Guidance for Industry: Oversight of Clinical Investigations --- A Risk-Based Approach to Monitoring, Section 5.3 -- Identification of Critical Data and Processes

SCDM GCDMP Chapter: Data Quality Assurance and Control -- Therapeutic Area--Specific Data Criticality Examples (Ophthalmology Studies)

Question 5

Question Type: MultipleChoice

What action should a data manager take if an investigator retires in the middle of an EDC trial and the replacement does not agree to use EDC for the remainder of the trial?

Options:

A- Notify the project manager and request that the site be closed.
B- Explore other options for the site with the study team.
C- Talk with the clinical research associate to identify alternative sites.
D- Discuss the use of the site's data with the project statistician.

Answer:

B

Explanation:

When an investigator retires mid-study and the replacement refuses to use the Electronic Data Capture (EDC) system, the data manager must not take unilateral action but rather collaborate with the study team to explore acceptable solutions.

Per the GCDMP (Chapter: Project Management in Data Management), any deviation from the established data capture method --- particularly a change that affects regulatory compliance, data consistency, or site operations --- requires a cross-functional assessment. The study team, which includes clinical operations, project management, regulatory affairs, and data management, should evaluate feasible alternatives such as:

Allowing paper CRF entry followed by centralized data transcription,

Retraining site staff on EDC use, or

Temporarily suspending data entry until compliance can be restored.

Immediate site closure (option A) or unilateral decisions by data management (options C and D) violate escalation and communication protocols. Collaborative decision-making ensures continuity, compliance, and data integrity, in line with ICH E6 (R2) GCP and FDA 21 CFR Part 11.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Project Management and Communication, Section 5.2 -- Handling Site and Investigator Changes

ICH E6 (R2) Good Clinical Practice, Section 4.1 -- Investigator Responsibilities

FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations -- Section on EDC Operations and Site Management

Question 6

Question Type: MultipleChoice

Which method would best identify inaccuracies in safety data tables for an NDA?

Options:

A- Compare counts of appropriate patients from manual CRFs to counts in table cells
B- Compare counts of appropriate patients from line listings of CRF data to counts in table cells
C- Review the tables to identify any values that look odd
D- Review the line listings to identify any values that look odd

Answer:

B

Explanation:

The best method for identifying inaccuracies in safety data tables prepared for a New Drug Application (NDA) is to compare counts of appropriate patients from line listings of CRF data to the counts in table cells.

According to the GCDMP (Chapter: Data Quality Assurance and Control), line listings represent raw, patient-level data extracted directly from the clinical database, whereas summary tables are aggregated outputs used for reporting and submission. Comparing these two sources ensures data traceability and accuracy, verifying that tabulated results correctly reflect the underlying patient data.

Manual CRF checks (option A) are less efficient and error-prone, as data entry is typically already validated electronically. Simply reviewing tables or listings for ''odd values'' (options C and D) lacks the systematic verification necessary for regulatory data integrity.

Thus, comparing line listings to tables (option B) provides a quantitative cross-check between the database and output deliverables, a standard practice in NDA data validation and statistical quality control.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 5.2 -- Validation of Tables, Listings, and Figures (TLFs)

FDA Guidance for Industry: Submission of NDA Safety Data, Section on Data Verification and Accuracy

ICH E6 (R2) GCP, Section 5.5.3 -- Validation of Derived Data Outputs

Question 7

Question Type: MultipleChoice

A study budgeted forty hours allocated over the three months following first protocol draft for Data Management Plan (DMP) creation. If there is a problem with this approach, what is it?

Options:

A- No time was allocated for maintenance of the DMP
B- Forty hours is too much time to budget for DMP creation
C- There is no problem with the approach
D- Forty hours is too little time to budget for DMP creation

Answer:

A

Explanation:

The main issue with this approach is that no time has been allocated for ongoing maintenance and updates of the Data Management Plan (DMP) throughout the study lifecycle.

According to the GCDMP (Chapter: Data Management Planning and Study Start-up), the DMP is a living document --- it must be continuously maintained and updated as study procedures evolve, particularly after protocol amendments, database modifications, or changes in data validation or reconciliation procedures.

Budgeting only for initial creation (forty hours) over three months ignores the substantial effort required for DMP version control, stakeholder communication, and mid-study updates. These updates are mandatory to maintain compliance with ICH E6 (R2) GCP Section 5.5.3, which requires that all procedural documentation accurately reflect current practices.

Thus, the problem is not the time allocated for creation but the lack of planning for ongoing maintenance.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Plan (DMP), Section 5.3 -- DMP Maintenance and Version Control

ICH E6 (R2) Good Clinical Practice, Section 5.5.3 -- Documentation of Data Handling Procedures

FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations -- Section on Documentation Updates

Question 8

Question Type: MultipleChoice

Which data are needed to monitor site variability in eligibility screening?

Options:

A- Number of sites with low enrollment
B- Number of subjects screened and number of subjects enrolled
C- Number of subjects enrolled
D- Number of sites with high enrollment

Answer:

B

Explanation:

To monitor site variability in eligibility screening, you must analyze the number of subjects screened versus the number of subjects enrolled at each site. This allows identification of sites that are over- or under-screening relative to their enrollment yield.

The GCDMP (Chapter: Data Quality Assurance and Metrics) emphasizes that screening-to-enrollment ratios are critical indicators of protocol compliance and data quality. Sites with unusually low conversion rates may have unclear understanding of inclusion/exclusion criteria, requiring targeted training or monitoring.

Other options (A, C, D) provide enrollment metrics but do not reveal screening efficiency or variability, which depend on both screening and enrollment data.

Thus, option B correctly identifies the data necessary for monitoring eligibility screening performance across sites.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: Data Quality Assurance and Metrics, Section 5.4 -- Site Performance Metrics

ICH E6(R2) GCP, Section 5.18 -- Monitoring and Site Oversight Requirements

Question 9

Question Type: MultipleChoice

For ease of data processing, the study team would like the database codes for a copyrighted rating scale preprinted on the CRF. What is the most critical task that the CRF designer must do to ensure the data collected on the CRF for the scale are reliable and will support the results of the final analysis?

Options:

A- Consult the independent source and determine database codes will not influence subject responses.
B- Consult the study statistician regarding the change and determine that database codes will not influence the analysis.
C- Consult the independent source of the rating scale for approval and document that continued validity of the tool is not compromised.
D- Complete the requested changes to the instrument and ensure the correct database codes are associated with the appropriate responses.

Answer:

C

Explanation:

When using a copyrighted or validated rating scale (e.g., Hamilton Depression Scale, Visual Analog Pain Scale), any modification to the original instrument, including preprinting database codes on the CRF, must be approved by the instrument's owner or licensing authority to ensure the validity and reliability of the instrument are not compromised.

According to the GCDMP (Chapter: CRF Design and Data Collection), validated rating scales are psychometrically tested tools. Any visual or structural modification (such as adding codes, changing layout, or rewording questions) can invalidate prior validation results. Therefore, the CRF designer must consult the independent source (copyright holder) for approval and document that the validity of the tool remains intact.

Merely consulting statisticians (option B) or verifying database alignment (option D) does not ensure compliance. Thus, Option C ensures scientific and regulatory integrity.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 6.1 -- Use of Validated Instruments and Rating Scales

ICH E6 (R2) GCP, Section 5.5.3 -- Validation of Instruments and Data Capture Tools

FDA Guidance for Industry: Patient-Reported Outcome Measures -- Use in Medical Product Development to Support Labeling Claims, Section 4 -- Instrument Modification and Validation